IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. decreased its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 39.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,720 shares of the company’s stock after selling 4,968 shares during the quarter. Principal Financial Group Inc.’s holdings in IDEAYA Biosciences were worth $245,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Nisa Investment Advisors LLC raised its stake in shares of IDEAYA Biosciences by 38.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,340 shares of the company’s stock worth $117,000 after buying an additional 927 shares during the period. Quest Partners LLC acquired a new position in IDEAYA Biosciences during the second quarter worth $41,000. Price T Rowe Associates Inc. MD lifted its holdings in IDEAYA Biosciences by 13.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,052,500 shares of the company’s stock valued at $177,825,000 after purchasing an additional 486,222 shares in the last quarter. Scientech Research LLC grew its position in shares of IDEAYA Biosciences by 362.3% in the second quarter. Scientech Research LLC now owns 27,708 shares of the company’s stock valued at $973,000 after purchasing an additional 21,714 shares during the period. Finally, D. E. Shaw & Co. Inc. raised its position in shares of IDEAYA Biosciences by 34.4% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 884,538 shares of the company’s stock worth $31,056,000 after purchasing an additional 226,514 shares during the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Down 0.9 %

Shares of IDEAYA Biosciences stock opened at $26.54 on Tuesday. The business’s fifty day simple moving average is $30.18 and its 200-day simple moving average is $35.64. The firm has a market cap of $2.29 billion, a PE ratio of -11.39 and a beta of 0.86. IDEAYA Biosciences, Inc. has a 52 week low of $25.20 and a 52 week high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.03. During the same quarter in the previous year, the business posted ($0.46) EPS. As a group, equities analysts expect that IDEAYA Biosciences, Inc. will post -2.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, September 24th. Leerink Partnrs cut shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 5th. Stephens assumed coverage on shares of IDEAYA Biosciences in a research report on Monday, November 18th. They set an “overweight” rating and a $51.00 price target on the stock. Citigroup dropped their price objective on shares of IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating for the company in a research note on Tuesday, August 27th. Finally, Oppenheimer reissued an “outperform” rating and issued a $53.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, October 29th. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, IDEAYA Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $53.67.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.